Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.

Sepsis remains one of the leading causes of mortality in critically ill patients. Increased insight into the complexities of this disease process has resulted in the targeting of various aspects of the inflammatory response as offering potential therapeutic benefits. There have been encouraging results in the past few years. Some of the tested agents have been shown to improve mortality rates in large randomized controlled trials involving patients with severe sepsis. In this article, we discuss the positive and negative results of trials in this field; some of the possible reasons for the negative results are examined, and directions for the future are suggested.

[1]  K. Reinhart,et al.  Is it Beneficial to Augment or to Inhibit Neutrophil Function in Severe Infections and Sepsis , 1997 .

[2]  P. Zabel,et al.  Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. , 1998, Archives of surgery.

[3]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[4]  M. Rafferty,et al.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. , 2000, Blood.

[5]  L. Thijs,et al.  Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma , 1998, The Lancet.

[6]  C. Chopin,et al.  Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. , 1993, Chest.

[7]  S. Hoffman,et al.  Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. , 1984, The New England journal of medicine.

[8]  S. Opal,et al.  High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .

[9]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[10]  J. Vincent,et al.  Hemofiltration in Sepsis and Septic Shock , 1997 .

[11]  H. Vetter,et al.  The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients , 2000, Intensive Care Medicine.

[12]  C. Hack,et al.  Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. , 1994, Progress in clinical and biological research.

[13]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[14]  S. Willatts,et al.  Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. , 1996, Critical care medicine.

[15]  C. Thiemermann,et al.  Comparison of the effects of aminoguanidine and N omega-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. , 1996, European journal of pharmacology.

[16]  G. Bernard,et al.  The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. , 1997, The New England journal of medicine.

[17]  J. Bertrand,et al.  Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. , 1996, Critical care medicine.

[18]  J. L. Rodriguez,et al.  A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients☆ , 1992 .

[19]  M. Schaller,et al.  Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. , 1998, Critical care medicine.

[20]  K. Asadullah,et al.  Monocyte deactivation in septic patients: Restoration by IFN-γ treatment , 1997, Nature Medicine.

[21]  S. Opal,et al.  Human neutrophil bactericidal/permeability‐increasing protein reduces mortality rate from endotoxin challenge: A placebo‐controlled study , 1994, Critical care medicine.

[22]  M. Hibberd,et al.  4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease , 1999, The Lancet.

[23]  H. Bruining,et al.  Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. , 1998, Shock.

[24]  H. Bruining,et al.  Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome. , 1997, Renal failure.

[25]  M. Murray,et al.  Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. , 1999, Critical care medicine.

[26]  K. Reinhart,et al.  Influence of N‐acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: Results from a prospective, randomized, double‐blind study , 1994, Critical care medicine.

[27]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[28]  S. Moncada,et al.  L-arginine: nitric oxide pathway in endotoxemia and human septic shock. , 1995, Critical care medicine.

[29]  A. Agustí,et al.  Effects of N-acetylcysteine on tissue oxygenation in patients with multiple organ failure and evidence of tissue hypoxia. , 1997, The European respiratory journal.

[30]  J. Vincent,et al.  Administration of Methylene Blue in Septic Shock: Is it Beneficial? , 1994 .

[31]  H. Bruining,et al.  p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. , 1997, JAMA.

[32]  R. Bellomo,et al.  Continuous veno‐venous hemofiltration with dialysis removes cytokines from the circulation of septic patients , 1993, Critical care medicine.

[33]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[34]  J. Carlet,et al.  INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.

[35]  J. Vincent.  Search for effective immunomodulating strategies against sepsis , 1998, The Lancet.

[36]  C. Dalay,et al.  The relationship between tumor necrosis factor (TNF)-alpha and survival following granulocyte-colony stimulating factor (G-CSF) administration in burn sepsis. , 2000, Burns : journal of the International Society for Burn Injuries.

[37]  Methylene blue reverses endotoxin-induced hypotension. , 1994 .

[38]  V. Pettilä,et al.  Protein C in the treatment of coagulopathy in meningococcal disease. , 1998, Critical care medicine.

[39]  J. Dhainaut,et al.  Platelet‐activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double‐blind, placebo‐controlled, multicenter clinical trial , 1994 .

[40]  T. Nakamura,et al.  Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  G. Koch,et al.  Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .

[42]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[43]  W. Buurman,et al.  Increased concentrations of cytokines and adhesion molecules in patients after repair of abdominal aortic aneurysm. , 1996, The European journal of surgery = Acta chirurgica.

[44]  S. Belknap,et al.  A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998 .

[45]  G. Steinmann,et al.  Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. , 1998, Critical care medicine.

[46]  J. Vincent,et al.  Yearbook of Intensive Care and Emergency Medicine , 1995, Yearbook of Intensive Care and Emergency Medicine.

[47]  N. Maekawa,et al.  Aminoguanidine attenuates endotoxin-induced acute lung injury in rabbits. , 1998, Critical care medicine.

[48]  I. Schedel,et al.  Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. , 1993 .

[49]  J. Vincent,et al.  Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study , 2001, Critical care medicine.

[50]  J. Lorente,et al.  L‐arginine pathway in the sepsis syndrome , 1993, Critical care medicine.

[51]  Phil Barton,et al.  Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial , 2000, The Lancet.

[52]  J. Vincent,et al.  An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock , 1999 .

[53]  D. Lalloo,et al.  Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. , 1996, The New England journal of medicine.

[54]  S A Conrad,et al.  Liposomal prostaglandin E1 in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. , 1996, Critical care medicine.

[55]  P. Suter,et al.  N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. , 1994, Chest.

[56]  S. Moncada,et al.  Effects of a nitric oxide synthase inhibitor in humans with septic shock. , 1994, Cardiovascular research.

[57]  A. Cerami,et al.  Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. , 1988, Surgery.

[58]  A. Hoeft,et al.  Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. , 1999, Critical care medicine.

[59]  G. Bernard,et al.  Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. , 1991, The American review of respiratory disease.

[60]  T. Babineau,et al.  Randomized Phase I/II Trial of a Macrophage‐Specific Immunomodulator (PGG‐Glucan) in High‐Risk Surgical Patients , 1994, Annals of surgery.

[61]  M. Lamy,et al.  Sepsis and serum cytokine concentrations. , 1997, Critical care medicine.

[62]  H. Bruining,et al.  Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. , 1998, Critical care medicine.

[63]  M. Nabuurs,et al.  HIGH VOLUME HEMOFILTRATION IMPROVES HEMODYNAMICS AND SURVIVAL OF PIGS EXPOSED TO GUT ISCHEMIA AND REPERFUSION , 1994, Shock.

[64]  E. P. Dellinger,et al.  Effect of PGG-glucan on the rate of serious postoperative infection or death observed after high-risk gastrointestinal operations. Betafectin Gastrointestinal Study Group. , 1999, Archives of surgery.

[65]  W. Sibbald,et al.  Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis. , 1997, Critical care medicine.

[66]  A. Tres,et al.  Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. , 2001, Journal of the National Cancer Institute.

[67]  M. Haupt,et al.  Effect of ibuprofen in patients with severe sepsis: A randomized, double‐blind, multicenter study , 1991, Critical care medicine.

[68]  R. W. Pryor,et al.  Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus‐induced septicemia in immature swine , 1993, Critical care medicine.

[69]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[70]  T. Babineau,et al.  A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. , 1994, Archives of surgery.

[71]  W. Knaus,et al.  Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. , 1997, JAMA.

[72]  F. Cerra,et al.  Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. , 1995, Critical care medicine.

[73]  J. Fierer,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1982, The New England journal of medicine.

[74]  I. Ebihara,et al.  Hemoperfusion with Polymyxin B- Immobilized Fiber Attenuates the Increased Plasma Levels of Thrombomodulin and von Willebrand Factor from Patients with Septic Shock , 1998, Blood Purification.

[75]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[76]  J. Moran,et al.  N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. , 1996, Critical care medicine.

[77]  R. Bone,et al.  Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome , 1989 .

[78]  D. Metz,et al.  Characterization of gastrointestinal bleeding in severely ill hospitalized patients , 2000, Critical care medicine.

[79]  J. McCutchan,et al.  PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID , 1985, The Lancet.

[80]  J. Murray,et al.  Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.

[81]  J. Vincent,et al.  Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis , 1993, Critical care medicine.

[82]  J. Peters,et al.  Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNFα plasma concentrations , 1997, Intensive Care Medicine.

[83]  A. Janoff,et al.  Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[84]  T. Butler,et al.  Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.

[85]  D. Inthorn,et al.  ANTITHROMBIN III SUPPLEMENTATION IN SEVERE SEPSIS: BENEFICIAL EFFECTS ON ORGAN DYSFUNCTION , 1997, Shock.

[86]  M. Bergeron,et al.  A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. , 2000, The Journal of infectious diseases.

[87]  K. Busch,et al.  Endotoxin Adsorbant Based on Immobilized Human Serum Albumin , 1999, Clinical chemistry and laboratory medicine.

[88]  J. Vincent,et al.  Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factor-alpha attenuation during endotoxic shock. , 1999, Critical care medicine.

[89]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[90]  R. Wunderink,et al.  Filgrastim in patients with pneumonia and severe sepsis or septic shock. , 2001, Chest.

[91]  M. Yu,et al.  A double‐blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome , 1993, Critical care medicine.

[92]  C. Pichard,et al.  Immunonutrition in the critically ill , 1999, Intensive Care Medicine.

[93]  C. Hack,et al.  Proteolytic inactivation of plasma C1- inhibitor in sepsis. , 1989, The Journal of clinical investigation.

[94]  S. Grey,et al.  Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. , 1994, Journal of immunology.

[95]  J. Schopohl,et al.  Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. , 1999, Critical care medicine.

[96]  M. Braga,et al.  Rational base and clinical results of immunonutrition. , 2000, Minerva Anestesiologica.

[97]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[98]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[99]  J. Vincent,et al.  Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock. , 2001, The American journal of medicine.

[100]  A. Combes,et al.  Selenium, systemic immune response syndrome, sepsis, and outcome in critically ill patients. , 1998, Critical care medicine.

[101]  P. Howdle,et al.  The effects of intravenous antioxidants in patients with septic shock. , 1997, Free radical biology & medicine.

[102]  L. Nelson,et al.  Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. , 1999, Critical care medicine.

[103]  P. Suter,et al.  Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. , 1997, Journal of critical care.

[104]  J. Cavaillon,et al.  Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide , 1993, The Journal of experimental medicine.

[105]  N. Mayer,et al.  Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. , 1997, Critical care medicine.

[106]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[107]  G. Rivard,et al.  Treatment of purpura fulminans in meningococcemia with protein C concentrate. , 1995, The Journal of pediatrics.

[108]  M. Carraway,et al.  Antibody to E- and L-selectin does not prevent lung injury or mortality in septic baboons. , 1998, American journal of respiratory and critical care medicine.

[109]  H. Polk,et al.  Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. , 1991, Surgery.

[110]  J. Cohen,et al.  Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. , 1999, British medical bulletin.

[111]  J. Vincent,et al.  Methylene blue administration in septic shock: A clinical trial , 1995 .

[112]  F. Lewis,et al.  Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. , 1994, Archives of surgery.

[113]  S. Morgera,et al.  Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration , 1997, Intensive Care Medicine.

[114]  S. Nasraway,et al.  Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.

[115]  J. Dhainaut,et al.  Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. , 1999, JAMA.

[116]  C. Natanson,et al.  Continuous arteriovenous hemofiltration does not improve survival in a canine model of septic shock. , 1995, Journal of the American College of Surgeons.

[117]  G. Bernard,et al.  A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. , 1997, Chest.

[118]  A. Groeneveld,et al.  Methylene blue increases myocardial function in septic shock. , 1995, Critical care medicine.

[119]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[120]  S. Goldfarb,et al.  Proinflammatory cytokines and hemofiltration membranes. , 1994, Journal of the American Society of Nephrology : JASN.

[121]  J. Vincent,et al.  Administration of an antibody to E-selectin in patients with septic shock. , 1996, Critical care medicine.

[122]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[123]  R. Gamelli,et al.  Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. , 1998, Critical care medicine.

[124]  J. Vincent,et al.  Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. , 1992, Chest.

[125]  T. Fabian,et al.  A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications. , 1996, Annals of surgery.

[126]  S. Nasraway,et al.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.

[127]  W. Schumer.  Steroids in the Treatment of Clinical Septic Shock , 1976, Annals of surgery.

[128]  P. Bollaert,et al.  Reversal of late septic shock with supraphysiologic doses of hydrocortisone. , 1998, Critical care medicine.

[129]  D. J. Bryg,et al.  An immune‐enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients , 2000, Critical care medicine.

[130]  G. Bernard,et al.  N-acetylcysteine in experimental and clinical acute lung injury. , 1991, The American journal of medicine.

[131]  C. E. Ettingshausen,et al.  Replacement Therapy with Protein C Concentrate in Infants and Adolescents with Meningococcal Sepsis and Purpura Fulminans , 1999, Seminars in thrombosis and hemostasis.

[132]  S. Bucklin,et al.  Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia , 1995, Antimicrobial agents and chemotherapy.

[133]  R. Lefering,et al.  Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.

[134]  J. Vincent,et al.  Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis , 2000, Critical care medicine.

[135]  J. Saffle,et al.  Randomized trial of immune-enhancing enteral nutrition in burn patients. , 1997, The Journal of trauma.

[136]  T. Nakamura,et al.  Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: Decrease in plasma levels of soluble P-selectin, platelet factor 4 and β-thromboglobulin , 1999, Inflammation Research.

[137]  J. Vincent,et al.  A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome , 2001, Intensive Care Medicine.

[138]  P. Herlevsen,et al.  Antioxidant treatment with N‐acetylcysteine during adult respiratory distress syndrome: A prospective, randomized, placebo‐controlled study , 1992, Critical care medicine.

[139]  V. Pettilä,et al.  Protein C substitution in sepsis-associated purpura fulminans , 2000, Critical care medicine.